Clinical Trial Update: A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC). [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial investigating GB1211 with atezolizumab in non-small cell lung cancer is currently active and not recruiting, spanning Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• GB1211 (Galectin-3 inhibitor) (GB1211)

Snippet

Sponsor: Galecto Biotech AB | Conditions: Non-Small Cell Lung Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING